Compare Northrop Grumman Corporation (NOC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Northrop Grumman Corporation trades at $516.5 (market cap $73.16B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: Northrop Grumman Corporation pays a 1.92% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Northrop Grumman Corporation nearer its low. Which is the better fit depends on your goals.
| NOC | XBI | |
|---|---|---|
Market Cap | $73.16B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $768.02 | $169.55 |
52-Week Low | $496.02 | $93.43 |
Enterprise Value | $87.14B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $518.58, up 0.7% with strong earnings beats in recent quarters. Technical indicators show a bearish trend with oversold RSI signals, while fundamentals remain solid with 10.48% net margin and 26.96% ROE. The company maintains a record $105 billion backlog and raised guidance after strong Q2 results, supported by rising defense spending globally.
NOC presents a compelling value with a 16.37 P/E below industry averages and a $618.43 consensus price target implying 19% upside. Risks include execution on massive contracts and defense budget volatility, but analyst sentiment is strongly bullish with 57% buy ratings. The stock offers defensive growth exposure amid geopolitical tensions.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
